arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ABVC BIOPHARMA, INC.

ABVC
$1.02 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
64 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

ABVC BIOPHARMA, INC. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $26.0M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -11.5%
FCF / Share $-0.04
Trailing P/E
Price / Book 2.4x
FCF Yield
Debt / Equity 0.01
info Valuation on last close. End-of-day price, Aug 7, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$795.95K
↑ +104.5%
Net Income Profit after all expenses
$-1.56M
↓ -85.3%
Operating Margin Operating profit as % of sales
-146.8%
↓ -89.0%
FCF / Share Free cash flow per share
$-0.04
↑ +2.6%
Long-Term Debt Long-term obligations
$124.40K
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Financial Health
45
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 64 quarters